| Literature DB >> 27217622 |
Hualiang Zhong1, Jeffrey Adams2, Carri Glide-Hurst1, Hualin Zhang3, Haisen Li1, Indrin J Chetty1.
Abstract
Adaptive radiotherapy may improve treatment outcomes for lung cancer patients. Because of the lack of an effective tool for quality assurance, this therapeutic modality is not yet accepted in clinic. The purpose of this study is to develop a deformable physical phantom for validation of dose accumulation algorithms in regions with heterogeneous mass. A three-dimensional (3D) deformable phantom was developed containing a tissue-equivalent tumor and heterogeneous sponge inserts. Thermoluminescent dosimeters (TLDs) were placed at multiple locations in the phantom each time before dose measurement. Doses were measured with the phantom in both the static and deformed cases. The deformation of the phantom was actuated by a motor driven piston. 4D computed tomography images were acquired to calculate 3D doses at each phase using Pinnacle and EGSnrc/DOSXYZnrc. These images were registered using two registration software packages: VelocityAI and Elastix. With the resultant displacement vector fields (DVFs), the calculated 3D doses were accumulated using a mass-and energy congruent mapping method and compared to those measured by the TLDs at four typical locations. In the static case, TLD measurements agreed with all the algorithms by 1.8% at the center of the tumor volume and by 4.0% in the penumbra. In the deformable case, the phantom's deformation was reproduced within 1.1 mm. For the 3D dose calculated by Pinnacle, the total dose accumulated with the Elastix DVF agreed well to the TLD measurements with their differences <2.5% at four measured locations. When the VelocityAI DVF was used, their difference increased up to 11.8%. For the 3D dose calculated by EGSnrc/DOSXYZnrc, the total doses accumulated with the two DVFs were within 5.7% of the TLD measurements which are slightly over the rate of 5% for clinical acceptance. The detector-embedded deformable phantom allows radiation dose to be measured in a dynamic environment, similar to deforming lung tissues, supporting the validation of dose mapping and accumulation operations in regions with heterogeneous mass, and dose distributions.Entities:
Keywords: Adaptive radiation therapy; dose accumulation; quality assurance
Year: 2016 PMID: 27217622 PMCID: PMC4870999 DOI: 10.4103/0971-6203.181641
Source DB: PubMed Journal: J Med Phys ISSN: 0971-6203
Figure 1(a) Lung phantom; (b) planning target volume consisting of tumor volume on the maximum intensity projection dataset plus 5 mm isotropic margin
Figure 2Thermoluminescent dosimeter points of measurement: (a) Tumor point in an axial cut; (b) inferior (DP-1), superior (DP-2) and posterior (DP-3) points in a sagittal cut
Figure 3The axial cut of the end-exhale phase images in (a) the first four-dimensional computed tomography scan, and (b) the second four-dimensional computed tomography scan; (c) the overlay of the two images in (a) and (b); (d-f) the sagittal cuts of the images shown in (a-c); (g) the computed tomography image intensity of the sponge in Pinnacle (X) versus the number of voxels (Y)
Figure 4(a) An axial cut of the end-inhale image; (b) and (c) the Elastix and VelocityAI-warped end-exhale images subtracted by the end-inhale image; (d-f) the sagittal cuts corresponding to (a-c)
Figure 5(a) The profiles of the Pinnacle doses calculated on the images of phase 0, 25, 50 and 75; (b) the profiles of the doses accumulated with the Elastix and VelocityAI algorithms; (c) the profiles of the Z-displacements from the Elastix and VelocityAI registrations
The mean difference (δ) and standard deviation (σ) between the displacement vector fields of the Elastix and VelocityAI-based deformable registrations performed from phase 0 to phase i, i=25, 50, and 75
Figure 6Iso-dose lines calculated by (a) Pinnacle and (b) EGSnrc/DOSXYZnrc
The thermoluminescent dosimeter measured doses (cGy) and computed doses were compared at four static points: SP-T, SP-A, SP-B, and SP-C
The accumulated doses were compared to their thermoluminescent dosimeter measurements at the four locations: DP-T, DP-1, DP-2, and DP-3